arcadeworld| Tianfeng Securities: The pharmaceutical distribution sector is expected to usher in valuation repairs

News summary

[Tianfeng Securities: The pharmaceutical distribution sector is expected to usher in valuation repair] Securities Times e Company News, Tianfeng Securities Research News believes that the pharmaceutical distribution sector is expected to usher in valuation repair due to the increase in the proportion of contributions from the second growth curve and the improvement of endogenous efficiency driven by national reform. The valuation of the distribution sector has been at a low level for a long timearcadeworld...

Newsletter text

[Tianfeng Securities: The pharmaceutical distribution sector is expected to usher in valuation repair] Securities Times e Company News, Tianfeng Securities Research News believes that the pharmaceutical distribution sector is expected to usher in valuation repair due to the increase in the proportion of contributions from the second growth curve and the improvement of endogenous efficiency driven by national reform. The valuation of the distribution sector has been in a low position for a long time, mainly due to factors such as the normalization of drug volume procurement, which has led to a compression of the industry's gross profit space; in recent years, leading companies have actively explored new business formats, making the pharmaceutical industry, pharmaceutical retail, and CSO more profitable.arcadeworldThe growth of new businesses of our company is impressive and is expected to substantially drive an increase in profit levels; at the same time, the new round of national reform focuses on improving profitability, and circulation companies, mainly state-owned enterprises, are expected to see valuation repairs. It is recommended to pay attention to national circulation enterprises with wide regional coverage and state-owned enterprise leaders with greater flexibility for improvement: Jiuzhitong, Sinopharm Tongyi, Liuyao Group, Shanghai Pharmaceutical, China Resources Pharmaceutical, and Chongqing Pharmaceutical Holdings.